Upholding the Principles of Autonomy, Beneficence, and Justice in Phase I Clinical Trials

Por Owonikoko, Taofeek K.
Publicado em 2013

Immune checkpoint inhibitors in small cell lung cancer

Por Pakkala, Suchita, Owonikoko, Taofeek K.
Publicado no J Thorac Dis (2018)

Immunotherapy of lung cancer

Por Owonikoko, Taofeek K., Borghaei, Hossein
Publicado no J Thorac Dis (2018)

Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation

Por Owonikoko, Taofeek K., Khuri, Fadlo R.
Publicado em 2013

Small Cell Lung Cancer: Therapies and Targets

Por Pillai, Rathi N, Owonikoko, Taofeek K
Publicado em 2013

Biomarkers and Targeted Systemic Therapies in Advanced Non-Small Cell Lung Cancer

Por Kumar, Mukesh, Vinicius, Ernani, Owonikoko, Taofeek K.
Publicado no Mol Aspects Med (2015)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Por Nazha, Bassel, Inal, Cengiz, Owonikoko, Taofeek K.
Publicado no Front Oncol (2020)

Taxanes: vesicants, irritants, or just irritating?

Por Barbee, Meagan S., Owonikoko, Taofeek K., Harvey, R. Donald
Publicado em 2014

Altered glutamine metabolism and therapeutic opportunities for lung cancer

Por Mohammed, Mohammed A., Deng, Xingming, Khuri, Fadlo R., Owonikoko, Taofeek K.
Publicado em 2013

What is the role of maintenance therapy in the treatment of non-small cell lung cancer?

Por Jiang, Yixing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Belani, Chandra P.
Publicado em 2010

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials

Por Chen, Zhengjia, Wang, Zhibo, Wang, Haibin, Owonikoko, Taofeek K, Kowalski, Jeanne, Khuri, Fadlo R
Publicado em 2013

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

Por Owonikoko, Taofeek K., Ramalingam, Suresh S., Kanterewicz, Beatriz, Balius, Trent, Belani, Chandra P., Hershberger, Pamela A.
Publicado em 2010

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Por Yao, Weilong, Yue, Ping, Zhang, Guojing, Owonikoko, Taofeek K., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Cancer Lett (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

Por Koo, Junghui, Wang, Xuerong, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Oncotarget (2015)

A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease

Por Bangaru, Saroja D., Kozarsky, Phyllis E., Lee, Daniel J., Sica, Gabriel L., Owonikoko, Taofeek K.
Publicado no World J Oncol (2015)

ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib

Por Li, Yiting, Zang, Hongjing, Qian, Guoqing, Owonikoko, Taofeek K., Ramalingam, Suresh R., Sun, Shi-Yong
Publicado no Cancer (2019)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing

Por Oh, You-Take, Deng, Jiusheng, Yue, Ping, Owonikoko, Taofeek K., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Oncogene (2015)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Por Zang, Hongjing, Qian, Guoqing, Arbiser, Jack, Owonikoko, Taofeek K., Ramalingam, Suresh S., Fan, Songqing, Sun, Shi‐Yong
Publicado no Mol Oncol (2020)

Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)

Por Zang, Hongjing, Qian, Guoqing, Zong, Dan, Fan, Songqing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong
Publicado no Cancer (2020)

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers

Por Gu, Jiajia, Yao, Weilong, Shi, Puyi, Zhang, Guojing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong
Publicado no Cancer (2020)